ArticleCurrent genomics2011
Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers.
Article in Current genomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 51 citations in OpenAlex.
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.The lancet. Diabetes & endocrinology · 2021Trial
- Endocrine-disrupting chemicals and thyroid cancer.Turkish journal of medical sciences · 2025Review
- Proteome-Wide Mapping of Artesunate Targets Reveals Enrichment of the Ubiquitin-Proteasome System.Drug design, development and therapy · 2025Article
- A novel role for nonactin: interfering with G-quadruplex in RET-driven medullary thyroid cancer.BMC cancer · 2024Article
- Molecular testing raises thyroid nodule fine needle aspiration diagnostic value.Endocrine connections · 2023Article
- Receptor tyrosine kinase inhibitors in cancer.Cellular and molecular life sciences : CMLS · 2023Review
- Metastatic medullary thyroid carcinoma: a new way forward.Endocrine-related cancer · 2022Review
- Systemic Therapy in Thyroid Cancer.Indian journal of surgical oncology · 2022Review
- A Benign Medullary Thyroid Cancer.Cureus · 2022Article
- Significance of chromogranin A and synaptophysin in medullary thyroid carcinoma.Bosnian journal of basic medical sciences · 2021Article
- Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with BothJournal of clinical research in pediatric endocrinology · 2021Article
- Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities.International journal of molecular sciences · 2021Review
- Multiplatform molecular test performance in indeterminate thyroid nodules.Diagnostic cytopathology · 2020Article
- Review
- Identification and interaction analysis of key miRNAs in medullary thyroid carcinoma by bioinformatics analysis.Molecular medicine reports · 2019Article
- Medullary Thyroid Carcinoma: Survival Analysis and Evaluation of Mutation-Specific Immunohistochemistry in Detection of Sporadic Disease.World journal of surgery · 2018Article
- Outcome of Treatment for Medullary Thyroid Carcinoma-a Single Centre Experience.Indian journal of surgical oncology · 2018Article
- Novel targeted therapies and immunotherapy for advanced thyroid cancers.Molecular cancer · 2018Review
- Oncogenesis of Thyroid CancerAsian Pacific journal of cancer prevention : APJCP · 2017Article
- An integrative study on the impact of highly differentially methylated genes on expression and cancer etiology.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medullary thyroid carcinoma (MTC) is a rare calcitonin producing neuroendocrine tumour that originates from the parafollicular C-cells of the thyroid gland. The RET proto-oncogene encodes the RET receptor tyrosine kinase, with consequently essential roles in cell survival, differentiation and proliferation. Somatic or germline mutations of the RET gene play an important role in this neoplasm in development of sporadic and familial forms, respectively. Genetic diagnosis has an important role in differentiating sporadic from familiar MTC. Furthermore, depending on the location of the mutation, patients can be classified into risk classes. Therefore, genetic screening of the RET gene plays a critical role not only in diagnosis but also in assessing the prognosis and course of MTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.